SOPHIA ANTIPOLIS, France—Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, reported net revenue of €0.8 million for third quarter ending Sept. 30, 2022. The revenue, which consists entirely of net royalty payments, was down from €2.4 million in the year ago period, including €0.7 million of net royalty payments and €1.7 million of licensing payments. Nicox also reported cash and cash equivalents of €25.6 million as compared with €42.0 million as of Dec. 31, 2021 and €31.6 million as of June 30, 2022.

The company estimates that it is financed until Oct. 31, 2023, and until November 30, 2023, assuming the extension of the interest-only period of the existing Kreos Capital debt. In both cases, continued financing is based on the development of its glaucoma drug, NCX 470, alone. Topline results of the NCX 470 Mont Blanc Phase 3 glaucoma trial are due in early November 2022.
 
As of Sept. 30, 2022, the Nicox Group had financial debt of €20.6 million consisting of €18.6 million in the form of a bond financing agreement with Kreos Capital signed in January 2019 and a €2 million credit agreement guaranteed by the French State in August 2020 in the context of the COVID-19 pandemic.